Aktis Oncology CEO to Present at Two March Investor Conferences
Event summary
- Aktis Oncology CEO Matthew Roden to present at TD Cowen and Leerink Partners investor conferences in March 2026.
- Presentations scheduled for March 3 in Boston and March 9 in Miami.
- Live webcasts available via Aktis' investor relations website.
- Company focuses on targeted radiopharmaceuticals for solid tumors.
The big picture
Aktis Oncology is positioning itself as a key player in the targeted radiopharmaceutical space, aiming to address unmet needs across multiple solid tumor types. The upcoming investor conferences provide a platform to showcase its proprietary miniprotein radioconjugate technology and strategic collaborations. The company's focus on expanding the potential of radiopharmaceuticals to larger patient populations aligns with broader industry trends toward precision oncology.
What we're watching
- Pipeline Progress
- How Aktis' presentations will highlight advancements in its AKY-1189 and AKY-2519 programs.
- Investor Sentiment
- Whether the conferences will boost confidence in Aktis' radioconjugate platform.
- Strategic Collaborations
- The impact of Aktis' partnership with Eli Lilly on its development pipeline.
Related topics